Treatment of pulmonary emboli: vena caval interruption or anticoagulation?
D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001728:Dicumarol / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008026:Ligation / Q000009:adverse effects; D011183:Postoperative Complications / Q000401:mortality; D011655:Pulmonary Embolism / Q000188:drug therapy / Q000517:prevention & control / Q000601:surgery / Q000628:therapy*; D012008:Recurrence; D014682:Vena Cava, Inferior / Q000601:surgery*; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D014859:Warfarin; D001728:Dicumarol; D006493:Heparin